Annual EBIT
-$3.16 M
+$94.09 M+96.75%
December 31, 2023
Summary
- As of February 7, 2025, TRDA annual earnings before interest & taxes is -$3.16 million, with the most recent change of +$94.09 million (+96.75%) on December 31, 2023.
- During the last 3 years, TRDA annual EBIT has risen by +$23.50 million (+88.14%).
- TRDA annual EBIT is now at all-time high.
Performance
TRDA EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$21.66 M
-$75.08 M-140.54%
September 30, 2024
Summary
- As of February 7, 2025, TRDA quarterly earnings before interest & taxes is -$21.66 million, with the most recent change of -$75.08 million (-140.54%) on September 30, 2024.
- Over the past year, TRDA quarterly EBIT has dropped by -$35.67 million (-254.57%).
- TRDA quarterly EBIT is now -140.54% below its all-time high of $53.42 million, reached on June 30, 2024.
Performance
TRDA Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
$57.78 M
-$35.67 M-38.17%
September 30, 2024
Summary
- As of February 7, 2025, TRDA TTM earnings before interest & taxes is $57.78 million, with the most recent change of -$35.67 million (-38.17%) on September 30, 2024.
- Over the past year, TRDA TTM EBIT has increased by +$91.43 million (+271.74%).
- TRDA TTM EBIT is now -38.17% below its all-time high of $93.45 million, reached on June 30, 2024.
Performance
TRDA TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
TRDA EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +96.8% | -254.6% | +271.7% |
| 3 y3 years | +88.1% | +15.3% | +159.4% |
| 5 y5 years | +73.3% | +15.3% | +159.4% |
TRDA EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +96.8% | -140.5% | +16.5% | -38.2% | +159.4% |
| 5 y | 5-year | at high | +96.8% | -140.5% | +16.5% | -38.2% | +159.4% |
| alltime | all time | at high | +96.8% | -140.5% | +16.5% | -38.2% | +159.4% |
Entrada Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$21.66 M(-140.5%) | $57.78 M(-38.2%) |
| Jun 2024 | - | $53.42 M(+153.0%) | $93.45 M(+293.8%) |
| Mar 2024 | - | $21.11 M(+330.4%) | $23.73 M(-850.5%) |
| Dec 2023 | -$3.16 M(-96.7%) | $4.91 M(-65.0%) | -$3.16 M(-90.6%) |
| Sep 2023 | - | $14.01 M(-186.0%) | -$33.65 M(-54.3%) |
| Jun 2023 | - | -$16.30 M(+182.0%) | -$73.59 M(-9.0%) |
| Mar 2023 | - | -$5.78 M(-77.4%) | -$80.88 M(-16.8%) |
| Dec 2022 | -$97.25 M | -$25.58 M(-1.4%) | -$97.25 M(+7.9%) |
| Sep 2022 | - | -$25.94 M(+10.0%) | -$90.13 M(+14.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$23.58 M(+6.5%) | -$78.56 M(+21.1%) |
| Mar 2022 | - | -$22.15 M(+20.0%) | -$64.89 M(+26.9%) |
| Dec 2021 | -$51.13 M(+91.7%) | -$18.46 M(+28.5%) | -$51.13 M(+23.7%) |
| Sep 2021 | - | -$14.36 M(+44.9%) | -$41.32 M(+21.8%) |
| Jun 2021 | - | -$9.91 M(+18.1%) | -$33.93 M(+41.3%) |
| Mar 2021 | - | -$8.39 M(-3.0%) | -$24.02 M(+53.7%) |
| Dec 2020 | -$26.67 M(+125.5%) | -$8.65 M(+24.1%) | -$15.63 M(+124.1%) |
| Sep 2020 | - | -$6.97 M | -$6.97 M |
| Dec 2019 | -$11.82 M | - | - |
FAQ
- What is Entrada Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Entrada Therapeutics?
- What is Entrada Therapeutics annual EBIT year-on-year change?
- What is Entrada Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Entrada Therapeutics?
- What is Entrada Therapeutics quarterly EBIT year-on-year change?
- What is Entrada Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Entrada Therapeutics?
- What is Entrada Therapeutics TTM EBIT year-on-year change?
What is Entrada Therapeutics annual earnings before interest & taxes?
The current annual EBIT of TRDA is -$3.16 M
What is the all time high annual EBIT for Entrada Therapeutics?
Entrada Therapeutics all-time high annual earnings before interest & taxes is -$3.16 M
What is Entrada Therapeutics annual EBIT year-on-year change?
Over the past year, TRDA annual earnings before interest & taxes has changed by +$94.09 M (+96.75%)
What is Entrada Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of TRDA is -$21.66 M
What is the all time high quarterly EBIT for Entrada Therapeutics?
Entrada Therapeutics all-time high quarterly earnings before interest & taxes is $53.42 M
What is Entrada Therapeutics quarterly EBIT year-on-year change?
Over the past year, TRDA quarterly earnings before interest & taxes has changed by -$35.67 M (-254.57%)
What is Entrada Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of TRDA is $57.78 M
What is the all time high TTM EBIT for Entrada Therapeutics?
Entrada Therapeutics all-time high TTM earnings before interest & taxes is $93.45 M
What is Entrada Therapeutics TTM EBIT year-on-year change?
Over the past year, TRDA TTM earnings before interest & taxes has changed by +$91.43 M (+271.74%)